FDA Approves Verrica Pharmaceuticals’ Ycanth

The U.S. Food and Drug Administration (FDA) approved Verrica Pharmaceuticals Inc.’s treatment Ycanth for a viral skin infection known as molluscum contagiosum in adults and children over two years old. Reuters explains, “The FDA decision is a boost in the arm for the company after it previously failed to secure marketing approval for the drug, which is delivered through a single-use applicator, allowing for precise topical dosing and targeted administration.” Furthermore, the U.S. has approved this drug as the first treatment for this disease, and they expect Verrica to become commercially available by September 2023. Additionally, in any given year, approximately six million Americans suffer from this disorder, primarily children.

The company is also testing Ycanth for treating common and external genital warts in ongoing late-stage trials. No price details have been released, but an analyst estimated a cost of around $500 per applicator.

To read more, click here.

What We’re Reading to Learn More:

• Verrica Slides After FDA Approval of Ycanth for Molluscum, Bloomberg Law 

• Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum, GlobalNewswire

• US FDA approves Verrica’s skin disease treatment, KFGO